+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 14 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are studying the effectiveness and safety of lorlatinib in patients with untreated ALK-positive non-small-cell lung carcinoma NSCLC. This research is conducted in a French real-world setting and sponsored by Pfizer. The study aims to assess how lorlatinib performs as a treatment option for this specific type of lung cancer. Participants will receive lorlatinib as a single-agent oral treatment at a dose of 100 mg daily. The study is designed as a single-group trial where patients continuously take lorlatinib. The treatment and observation period includes assessments up to 25 months, during which various outcomes such as progression-free survival, overall survival, response rates, and treatment duration will be evaluated. During the study, participants will be monitored regularly with imaging tests like CT scans and brain MRIs before starting treatment. Researchers will track treatment adherence, symptom changes, adverse events, and resistance mechanisms. Patient-reported outcomes and quality of life questionnaires will be collected at multiple time points up to 48 months. Safety and effectiveness measures will guide the ongoing evaluation, with follow-up visits scheduled throughout the study period.

Age: 18Years +All GendersPhase Not Applicable
32 locations
P

Actively Recruiting

Researchers are evaluating mechanical ventilation strategies and the timing of muscle relaxation in patients with moderate to severe Acute Respiratory Distress Syndrome ARDS. The study aims to test personalized approaches for setting Positive End-Expiratory Pressure PEEP based on lung recruitability and whether early use of neuromuscular blocking agents NMBAs during prone positioning improves survival compared to rescue use. This trial addresses the lack of specific treatments for ARDS and focuses on improving survival by optimizing ventilation methods. Participants will be assigned to different ventilation strategies routine care with minimal lung distension using low tidal volume and conservative PEEP, routine care with maximal lung recruitment adjusting tidal volume and PEEP to maintain safe plateau pressures, or a personalized PEEP strategy based on a PEEP responsiveness test. Additionally, the study compares early systematic use of NMBAs during prone positioning to rescue use. Two randomizations occur first for ventilation strategy and second for NMBA timing. During the study, participants will undergo mechanical ventilation with assigned strategies, and researchers will monitor oxygenation, respiratory parameters, organ function scores, and mortality over time. Assessments include arterial blood gases, tidal volumes, respiratory rates, and organ failure evaluations at multiple time points up to one year. The primary outcome is 28-day all-cause mortality. Safety and long-term outcomes such as disability, cognitive function, quality of life, and return to work status will also be evaluated throughout the follow-up period.

Age: 18Years +All GendersPhase Not Applicable
29 locations
C

Actively Recruiting

Researchers are investigating improved chemotherapy options for patients with metastatic Grade 3 poorly differentiated neuroendocrine carcinomas G3 NEC of the gastro-entero-pancreatic GEP system or unknown origin. These cancers are rare, often diagnosed at an advanced stage, and have limited treatment success with the current standard platinum-etoposide chemotherapy. The study aims to compare the mFOLFIRINOX regimen to the standard platinum-etoposide treatment and to explore molecular characteristics that might predict which patients respond best to each therapy. The trial compares two chemotherapy regimens mFOLFIRINOX, given every 14 days for up to 12 cycles, and platinum-etoposide, administered every 21 days for 6 to 8 cycles or up to 24 weeks. Both treatments are given intravenously on day 1 of each cycle, with continuation depending on disease progression and side effects. The mFOLFIRINOX regimen combines 5-fluorouracil, oxaliplatin, and irinotecan, while the platinum-etoposide regimen includes cisplatin or carboplatin plus etoposide. Molecular profiling of tumors will also be performed to identify biomarkers that may guide therapy choices. Participants will undergo regular scans and laboratory tests to monitor tumor response and side effects. Researchers will measure progression-free survival as the main outcome, along with overall survival, response rates, and treatment tolerability over up to 24 months. The study involves random assignment to one of the two treatment groups and requires ongoing monitoring to assess how well the therapies work and their safety in this patient population.

Age: 18Years +All GendersPhase 2
6 locations
S

Actively Recruiting

This research focuses on classifying genetic variants found in families with a history of hereditary cancer, especially breast and ovarian cancers. It aims to improve genetic counseling by studying the co-segregation of specific gene variants, including those in BRCA1, BRCA2, PALB2, and other genes tested in multigene panels. The study uses data from large French national databases to better understand the disease risk linked to these variants and to support clinical decision-making. Participants include index cases carrying variants of interest classified as class 3 variants of uncertain significance, class 4 likely pathogenic, or hypomorphic class 5 with intermediate effects. The study collects saliva samples from family members to test for these variants and applies statistical models to evaluate the likelihood that a variant causes disease. Genetic analyses are performed by partner laboratories, and results contribute to refining variant classification and recommendations. During the study, participants provide saliva samples for genetic testing and consent to share their data anonymously for analysis. Researchers monitor co-segregation of variants with disease in families over up to 15 years. The main outcome is the classification of selected variants based on family data, which may impact genetic counseling and clinical management. Results are shared at the group level without revealing individual test outcomes.

Age: 18Years +All GendersPhase Not Applicable
62 locations
O

Actively Recruiting

Researchers are studying adult patients with unresectable or metastatic HER2-low and HER2-ultralow expressing breast cancer who have either received prior chemotherapy in the metastatic setting or have hormone receptor-positive disease not suitable for endocrine therapy. The study aims to observe the real-world use and effects of Trastuzumab deruxtecan T-DXd and conventional chemotherapy in these populations. This observational study collects data without administering any study drugs directly, focusing on patient characteristics, treatment patterns, and safety. Participants will be grouped into those receiving T-DXd according to approved medical guidelines and those treated with conventional chemotherapy, including drugs like capecitabine and paclitaxel. The study records treatment details and the management of any adverse reactions, with Group 2 patients contributing baseline data on conventional chemotherapy. Treatments are given as part of routine clinical care, following the Summary of Product Characteristics, without experimental interventions. During the study, participants treatment courses will be tracked for up to approximately 37 months. Researchers will evaluate the time to next treatment, treatment discontinuation, safety events, and patients impressions of treatment tolerability and quality of life. Data collection includes physician reports, patient diaries, and quality of life questionnaires. This long-term monitoring helps to understand treatment patterns and patient experiences in real-world settings.

Age: 18Years +All Genders
216 locations
S

Actively Recruiting

Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults who have type 2 diabetes, high blood pressure, and established cardiovascular disease but no history of heart failure. This study aims to understand if this combination can reduce the risk of cardiovascular events compared to a placebo combined with empagliflozin. Participation is randomized and double-blinded to compare these treatments fairly. Participants are randomly assigned to one of two groups one takes vicadrostat plus empagliflozin, and the other takes placebo tablets that look like vicadrostat plus empagliflozin. They take one tablet daily for a period ranging from two and a half years up to four years and three months. All participants continue their regular medications for diabetes, hypertension, and cardiovascular disease alongside the study treatments. Throughout the study, participants attend regular visits where their health is carefully monitored. Doctors collect information about cardiovascular events and take blood samples. They also track any side effects and changes in blood pressure and kidney function. The main outcome is the time until the first cardiovascular death or heart failure event, observed over up to 51 months. Participants stay in the study for up to four years and three months with ongoing health assessments.

Age: 18Years +All GendersPhase 3
1142 locations
S

Actively Recruiting

Researchers are investigating the best length of prednisone treatment for patients with granulomatosis with polyangiitis GPA and microscopic polyangiitis MPA, serious autoimmune diseases that can relapse and cause damage despite current treatments. Rituximab is commonly used to maintain remission, but the ideal duration for prednisone therapy remains unclear. This trial is the first prospective study to compare longer versus shorter prednisone use as an add-on to remission maintenance in these conditions. Participants will receive either prednisone 5 mg per day or a placebo for 12 months, with dosing beginning on Day 1. Prednisone dosage will be tapered by 1 mg per week until complete withdrawal after 12 months. The study is randomized, double-blind, and placebo-controlled, evaluating the impact of extended prednisone use alongside rituximab maintenance therapy. During the 30-month study period, participants will be monitored for relapse-free survival, defined by a disease activity score BVAS greater than zero. Researchers will also assess serious adverse events, glucocorticoid-related complications like fractures and weight gain, vasculitis relapse rates, prednisone use, bone density, disease damage, functional disability, quality of life, and healthcare resource use. Assessments include clinical evaluations and standardized questionnaires to track disease status and treatment effects over time.

Age: 18Years +All GendersPhase Not Applicable
45 locations
E

Actively Recruiting

Researchers are studying genetic factors linked to early-onset cancer, focusing on patients with either inherited or spontaneous genetic alterations that may increase cancer risk. This study aims to evaluate a new genetic testing method called high-throughput exome sequencing SHD-E after standard gene panel tests fail to identify a genetic cause. The goal is to see if SHD-E can find additional genetic changes that contribute to cancer predisposition in patients diagnosed at a young age. Participants will undergo one genetic consultation and provide a blood sample for analysis. This approach is being assessed for patients diagnosed with cancer before age 40 or before age 30 for breast cancer who had negative results from routine gene panel tests. The study may also include tumor samples and, when necessary, testing of parents or affected relatives to support genetic analysis. During the study, participants will have their genetic mutations evaluated to identify new cancer risk factors. The study involves reviewing the genetic data collected from blood tests and possibly tumor samples. Participants must consent to join and be affiliated with a social security scheme. The primary outcome measured is the identification of genetic mutations that may explain cancer predisposition in these early-onset cases.

Age: 18Years +All GendersPhase Not Applicable
6 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating three different approaches to improve cervical cancer screening participation among women aged 30 to 65 years living in two French departments. The study compares direct mailing of an HPV self-sampling kit, offering a choice between self-sampling or healthcare provider sampling, and the standard screening procedure. This randomized controlled trial aims to increase screening rates, assess feasibility, acceptability, and cost-effectiveness of these methods to inform the national screening program in France. Participants are randomly assigned to one of three groups the Outreach group receives a self-sampling kit directly by mail along with an SMS reminder if they do not participate within three months, plus assistance for follow-up cytology if HPV positive. The Choice group receives an invitation offering either to order a self-sampling kit or visit a healthcare provider, with reminders if they do not participate. The control group follows the standard invitation process with HPV self-sampling offered after a 12-month reminder if needed. Throughout the study, researchers will monitor participation rates at 18 months post-invitation, HPV positivity rates, completion of follow-up cytology, time to triage, and acceptability of self-sampling up to 24 months. Cost-effectiveness of each screening strategy will also be evaluated. Women will receive support for follow-up testing if needed, and reminders will encourage completion of screening steps. The total participation period lasts at least 24 months with ongoing data collection.

Age: 30Years - 65YearsFEMALEPhase Not Applicable
2 locations
A

Actively Recruiting

Bronchiectasis is a chronic lung condition where parts of the airways are permanently widened, causing mucus buildup, infections, and ongoing inflammation. This study evaluates the long-term use of the SIMEOX medical device at home, combined with remote physiotherapy, to improve quality of life and reduce lung flare-ups in adults with non-cystic fibrosis bronchiectasis. The research compares this approach to enhanced standard care including remote physiotherapy alone. Participants will be randomly assigned to either standard care with remote physiotherapy or to use the SIMEOX device daily at home alongside remote physiotherapy. Remote physiotherapy sessions occur once a month for the first three months and then every three months. The study spans an average of 24 months to assess the effects of adding the SIMEOX device to usual care. During the study, participants will complete quality of life questionnaires and undergo lung function tests at 6, 12, and 24 months. The main outcomes measured include the yearly rate of lung exacerbations and changes in quality of life scores. Researchers will also track hospitalizations, treatment compliance, adverse events, and lung function changes. The long follow-up aims to evaluate the sustained impact of the device and physiotherapy on participants respiratory health.

Age: 18Years +All GendersPhase Not Applicable
57 locations

1-10 of 14

1